RNAi-mediated gene silencing in non-human primates

Nature

Volumn 441, Issue 1, 2006, Pages 111-114

  Zimmermann, Tracy S ^a   Lee, Amy C H ^b   Akinc, Akin ^a   Bramlage, Birgit ^b   Bumcrot, David ^a   Fedoruk, Matthew N ^b   Harborth, Jens ^a   Heyes, James A ^b   Jeffs, Lloyd B ^b   John, Matthias ^a   Judge, Adam D ^b   Lam, Kieu ^b   McClintock, Kevin ^b   Nechev, Lubomir V ^a   Palmer, Lorne R ^b   Racie, Timothy ^a   Röhl, Ingo ^a   Seiffert, Stephan ^a   Shanmugam, Sumi ^a   Sood, Vandana ^b   Soutschek, Jürgen ^a   Toudjarska, Ivanka ^a   Wheat, Amanda J ^b   Yaworski, Ed ^b   Zedalis, William ^a   Koteliansky, Victor ^a   Manoharan, Muthiah ^a   Vornlocher, Hans Peter ^a   MacLachlan, Ian ^b   more..

^a ALNYLAM PHARMACEUTICALS   (United States)

^b Protiva Biotherapeutics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYMES; GENETIC ENGINEERING; NUCLEIC ACIDS; RNA; BIOLOGICAL ORGANS; CHOLESTEROL; DISEASES; DRUG DOSAGE; LIPIDS; MEDICINE; PROTEINS;

GENE SILENCING; NON-HUMAN PRIMATES; SERUM CHOLESTEROL; TARGET GENES; LIPOPROTEINS; RNA INTERFERENCES (RNAI); STABLE NUCLEIC ACID LIPID PARTICLES (SNALP);

GENES; GENETIC ENGINEERING;

APOLIPOPROTEIN B; CHOLESTEROL; LIPOSOME; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MISMATCH SMALL INTERFERING APOLIPOPROTEIN B 2; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG; LIPID;

DISEASE; DRUG DEVELOPMENT; GENE EXPRESSION; PRIMATE; PROTEIN; RNA; DOSE-RESPONSE RELATIONSHIP; GENETIC ENGINEERING; MAMMAL; MEDICINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOB GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; GENE; GENE SILENCING; GENE TARGETING; LIVER; MONKEY; NONHUMAN; PREDICTION; PRIMATE; PRIORITY JOURNAL; RNA INTERFERENCE; DOSE RESPONSE; GENE EXPRESSION; RNA CLEAVAGE; ANIMAL; GENETICS; METABOLISM; PHENOTYPE;

HARNESS; MACACA FASCICULARIS; PRIMATES; RODENTIA;

ANIMALS; APOLIPOPROTEINS B; PHENOTYPE; PRIMATES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 33646185371     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04688     Document Type: Article

References (19)

1. Novina, C. D. & Sharp, P. A. The RNAi revolution. Nature 430, 161-164 (2004).
2. Shankar, P., Manjunath, N. & Lieberman, J. The prospect of silencing disease using RNA interference. J. Am. Med. Assoc. 293, 1367-1373 (2005).
3. Thakker, D. R. et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl Acad. Sci. USA 101, 17270-17275 (2004).
4. Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nature Med. 11, 50-55 (2005).
5. Palliser, D. et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439, 89-94 (2006).
6. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
7. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23, 709-717 (2005).
8. Morrissey, D. V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol. 23, 1002-1007 (2005).
9. Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986).
10. Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
11. Ridker, P. M. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005).
12. Crooke, R. M. et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884 (2005).
13. Song, E. et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J. Virol. 77, 7174-7181 (2003).
14. Bartlett, D. W. & Davis, M. E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34, 322-333 (2006).
15. Lennernas, H. & Fager, G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32, 403-425 (1997).
16. Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84 (1999).
17. Chonn, A., Cullis, P. R. & Devine, D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146, 4234-4241 (1991).
18. Hornung, V. et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263-270 (2005).
19. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnol. 23, 457-462 (2005).